Faron Pharmaceuticals initiates second phase of BEXMAB study -Dr. Markku Jalkanen, CEO, Faron Pharmaceuticals 00:00:00
Dr. Markku Jalkanen has more than 30 years of experience within biomedical research, biotech development and the biopharmaceutical industry. He was a founding member of the Company and is its CEO. In addition to his role as CEO, he is an advisor for the only active Finnish life sciences fund, Inveni Capital. Between 1996 and 2002, Dr. Jalkanen was the founding CEO and President of BioTie Therapies Corporation, which become the first publicly traded Finnish biotech company in Helsinki to become listed on the US NASDAQ.
